Boston Scientific Reports Robust 2025 Sales, Positions Future Growth on Innovation

Boston Scientific Posts Strong 2025 Sales and Frames Future Growth Around Innovation

Boston Scientific reports robust fourth‑quarter and full‑year 2025 results, driven by broad product demand and continued investment in innovation. Fourth‑quarter net sales total $5.286 billion, up 15.9% reported and 12.7% organic year‑over‑year, while full‑year sales reach $20.074 billion, rising 19.9% reported and 15.8% organic. The company records GAAP net income of $672 million in the quarter and $2.898 billion for the year, and management says performance exceeds internal revenue guidance bands and reflects accelerating market traction across core franchises.

Management attributes the gains to sustained new product introductions, disciplined commercial execution and targeted R&D spend that strengthen clinical and market differentiation. Cardiovascular and MedSurg franchises both expand, with cardiovascular showing particularly strong momentum. Boston Scientific says its global teams are delivering “differentiated innovation and high performance,” and leadership frames 2025 as a year that not only surpasses goals but positions the company for continued expansion in procedures, device adoption and geographic reach.

The company emphasizes operational discipline alongside growth, balancing investment in product launches and market development with margin stewardship. Boston Scientific signals it will maintain R&D and commercialization activities to support long‑term revenue and margin expansion, while integrating performance improvements into manufacturing and supply chains. CEO Mike Mahoney highlights patient impact from new technologies as central to future growth, and the firm stresses that ongoing innovation is the principal lever for expanding treatment adoption globally.

Segment and regional performance detail continued momentum across businesses. Cardiovascular net sales rise 18.2% reported and 16.1% organic, while MedSurg grows 11.7% reported and 6.5% organic. By geography, the U.S. market expands about 17% reported and operational, and EMEA posts double‑digit reported growth while showing more modest operational gains, reflecting varied recovery and product mix dynamics across markets.

Product portfolio actions also feature in the company’s operational narrative. Boston Scientific notes it discontinued worldwide sales of the ACURATE neo2™ and ACURATE Prime™ valves in Q2 2025, a move management frames as part of portfolio optimization to focus resources on higher‑impact programs and future device rollouts that support broader clinical adoption.